Overall Risk Very High High Medium Low Very Low. In depth view into Adaptimmune Therapeutics Price Target including historical data from 2015, charts, stats and industry comps. Adapt is a global B2B contact and company database provider across multiple industries. The latest price target for Adaptimmune Therapeutics (NASDAQ: ADAP) was reported by SVB Leerink on 2020-11-05. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Earnings. Is ADAP a Buy, Hold or Sell? However i don't think today is the best day to get on the train. The shares outstanding are 154.87M, and float is at 11.25M with Short Float at 13.45%. Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. Adapt has 300,000+ users and 100 million business contacts, including industry-specific company database and contact information such as job title, direct dial, and email address. Based on 8 analysts offering 12 month price targets for NovoCure in the last 3 months. Dec-07-20 11:32PM : We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow . See low price in cart . 5.54. The variance in analysts' estimates of ADAP is lower than 6.2% of all US stocks. Comes with (one) reduced Pistol/556 paddle, (4) 1/4″ Bolts with nuts, (4) 3/16″ bolts with nuts, welded gusset assembly, instructions. -0.40 / -6.73%. Based on our forecasts, a long-term increase is expected, the "ADAP" stock price prognosis for 2026-02-27 is 7.687 USD. The upside potential (average analyst target price relative to current price) of ADAP is higher than 86.52% of all US stocks. It helps companies across the globe take control of their Marketing and Sales campaigns/strategies with industry-leading products. Choose options. Copyright © 2021. Target features the Thoracic Cavity or center of vital mass, the Cranial Ocular Cavity for immediate incapacitation, Trigger Diagnostic Wheel, Trigger Speed Bar, Shapes, Colors, and Numbers for reactive call-out drills. Simply Wall St. Dec-16-20 12:32PM : Is ADAP A Good Stock To Buy Now? ADAP updated stock price target summary. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types. 13.40. for only . On November 05, 2020 "SVB Leerink" gave "Market Perform" rating for ADAP. Zacks Investment Research raised shares of […] 173. Estimates (3) Low: Projected EPS: High-0.94-0.9-0.86: Details. Monthly Subscription. See the POWR Ratings now! At the current price of $6.77, shares in Adaptimmune Therapeutics are trading at … The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. volume What is stop-loss? Please note, it is not enough to conduct a financial or market analysis of a single entity such as Adaptimmune Ther. Choose options. Just click the link Price Target Impact on Share Price Details; 6/12/2019: HC Wainwright: Reiterated Rating: Hold Neutral: Low: 6/13/2018: Jefferies Financial Group: Downgrade: Buy Hold: $9.00 $2.00: High: 3/13/2018: Cantor Fitzgerald: Lower Price Target: Hold Overweight: $19.00 $5.00: High Simply Wall St. Dec-16-20 12:32PM : Is ADAP A Good Stock To Buy Now? Just enter your email address below. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! 744. On top of this, the average price target is $13.33, suggesting robust growth of ~236% from the current price of $3.97. You may find the need to stake your target base depending on the distance and calibers used as well as the plate size. Overall, ADAP continues to hold a Moderate Buy analyst consensus, with the Street evenly split between hold and buy. NASDAQ ADAP traded down $0.08 on Tuesday, hitting $6.75. NASDAQ ADAP traded down $0.08 on Tuesday, hitting $6.75. Ergobaby. ADAP: Get the latest Adaptimmune Therapeutics stock price and detailed information including ADAP news, historical charts and realtime prices. (See ADAP stock analysis on TipRanks). Simply Wall St. Nov-20-20 07:30AM : Adaptimmune to Showcase Market Potential for SPEAR T-cell … Institutions hold 84.04% of the Float. All 'A' Rated Buy Stocks, • 2 Little-Known Technology Stocks Rated Strong Buy, • 3 A-Rated Value Stocks to Buy Right Now, • 2 Retail Stocks to Buy in March, 2 to Avoid. The analyst firm set a price target for 6.00 expecting ADAP to rise to within 12 months (a possible 14.50% upside). Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Adrian Rawcliffe sold 9,879 shares of the firm’s stock in a transaction dated Tuesday, January 19th. Adaptimmune Therapeutics shares are trading higher after Baker Bros. Advisors reported a 6.4% passive stake in the company. ADAP has a greater average analyst price target than 23.84% of all US stocks. To see all exchange delays and terms of use, please see disclaimer. Your current $100 investment may be up to $153.43 in 2026. These price ends are -11.11% and +151.85% off the current price level respectively, although investors could be excited at the prospect of a +77.78% if the ADAP share price touches on the median price of $12. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Adrian Rawcliffe Sells 9,879 Shares. Adapt Academy Target #1 ADAPT-1; Target designed by ADAPT Academy of Defensive and Protective Training. Based on 5 analysts offering 12 month price targets for Kadmon Holdings in the last 3 months. We have 9 different ratings for every stock to help you Related News: The projected low price target is $6 while the price target rests at a high of $17. Please note, it is not enough to conduct a financial or market analysis of a single entity such as Adaptimmune Ther. Dec-07-20 11:32PM : We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow . With a 5-year investment, the revenue is expected to be around +53.43%. See low price in cart. The shares were sold at an average price of $5.67, for a total value of $56,013.93. Adaptimmune Therapeutics Q4 EPS $(0.04) Beats $(0.23) Estimate, Sales $1.50M Miss $1.98M Estimate, The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants, The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings, The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal. Monday, June 01, 2020. 1,457,161 shares of the company’s stock were exchanged, compared to its average volume of 1,256,764. Ergobaby 360 Baby Carrier - Pure Black. Adaptimmune Therapeutics shares were trading higher after Baker Bros. Advisors reported a 6.4% passive stake in the company. Support & Resistance - Acc. The stock has a market cap of $878.24 million, a price-to-earnings ratio of -6.90 and a beta of 2.40. The average price target for the stock over the next 12 months is $11.33, with the estimates having a low of $6 and a high of $17. Adaptimmune stock price target raised to $9 from $3 at Mizuho MarketWatch. Today’s Change. Adaptimmune Therapeutics's earnings in 2021 is -$122,843,000.On average, 3 Wall Street analysts forecast ADAP's earnings for 2021 to be $-943,465,356, with the lowest ADAP earning TARGET 1 Price: 10.32 Profit: 34.7% (Typical rally) Stop/Trailing Stop: 7.01 Loss: 8.5% P/L Ratio: 4.1 : 1 - Excellent Shares of companies in the broader healthcare sector are trading lower as stocks across sectors sell off amid a continued rise in yields following comments from Fed Chair Powell. Coronavirus update: Global case tally tops 6 million as weekend protests spark concerns they will lead to an increase in infections MarketWatch. The average price target for the stock over the next 12 months is $11.33, with the estimates having a low of $6 and a high of $17. During the day the stock fluctuated 7.29% from a day low at $5.35 to a day high of $5.74. Earnings. Over the past six months, the relative strength of its shares against the market has been -26.92%. Get today's Adaptimmune Therapeutics Plc stock price and latest ADAP news as well as Adaptimmune Therapeutics real-time stock quotes, technical analysis, full financials and more. ADI Target Price. Insider Monkey +6.88%. Free trial. Stock quotes, social news, market sentiment, and price targets for ADAP (Adaptimmune Therapeutics PLC - ADR). Analysts have given the company’s stock an average 52-week price target of $11.33, forecast between a low of $6 and high of $17. I believe that ADAP is slightly overbought at the moment and in the short term, it will correct in price. About ADAP. As of Feb 26. Average Share Price and Price Target by Month. Join. Get the latest Adaptimmune Therapeutics PLC ADAP detailed stock quotes, stock data, … Many experts also interview Adaptimmune Ther executives and customers to further validate their buy or sell advice. ET by Tomi Kilgore Adaptimmune's stock tumbles after plans for public stock offering Ergobaby. Estimates (3) Low: Projected EPS: High-0.94-0.9-0.86: Details. The average price target is $14.25 with a high forecast of $25.00 and a low forecast of $8.00.The average price target represents a 210.46% increase from the last price of $4.59. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. Equities analysts expect Adaptimmune Therapeutics plc (NASDAQ:ADAP) to announce ($0.23) earnings per share for the current quarter, according to Zacks. Find real-time ADAP - Adaptimmune Therapeutics PLC stock quotes, company profile, news and forecasts from CNN Business. The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $5.24 last updated Today at 6:41:57 PM. Adaptimmune Therapeutics plc (ADAP) estimates and forecasts They currently have an outperform rating on the biotechnology company’s stock. $139.99 . ... See low price in cart. 1, 2020 at 7:24 a.m. Adaptimmune Therapeutics Share Price - ADAP . 4 Wall Street analysts have set twelve-month price targets for Adaptimmune Therapeutics in the last year. $52.04. ADAP -- USA Stock : USD 6.29 0.31 5.18% : ... Target Price: High: 5.00: 9.25: 17.00: Details. Volatility 8.26 % Daily Average Volatility. $12 Flat Rate shipping in all 50 US states. Adaptimmune Therapeutics plc American Depositary Shares (ADAP) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Shares are priced at $14.95 and have an average price target of $29.50, which implies a one-year upside of ~97%. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. 4.7 out of 5 stars with 81 reviews. Small Cap Basic. Adapt IT Holdings Stock Forecast, ADI stock price prediction. 410. ADAP has a greater number of analysts covering the stock than 77.88% of stocks in the small market cap category. The average price target is $160.57 with a high forecast of $225.00 and a low forecast of $103.00.The average price target represents a 24.20% increase from the last price of $129.28. 4.5 out of 5 stars with 173 reviews. Detailed list of analyst forecasts ADAP: Get the latest Adaptimmune Therapeutics stock price and detailed information including ADAP news, historical charts and realtime prices. Adaptimmune Therapeutics PLC. above. The Average True Range (ATR) for Adaptimmune Therapeutics plc is set at 0.42, with the Price to Sales ratio for ADAP stock in the period of the last 12 months amounting to 275.67. The stock has a market cap of $878.24 million, a price-to-earnings ratio of -6.90 and a beta of 2.40. In that case, then, we find that the latest price level in today’s session is +143.2% off the targeted high while a plunge would see the stock lose -14.16% from current levels. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View our list of the best stock brokerages. He has a more bullish $15 price target on the stock, indicating further upside potential of 35%. Follow ADAP. Get today's Adapt IT Holdings Ltd stock price and latest ADIJ news as well as Adapt IT Holdings Ltd real-time stock quotes, technical analysis, full financials and more. Ergobaby Omni 360 All Carry Positions Ergonomic Baby Carrier - Pure Black. Adaptimmune Therapeutics’s Q1 earnings are confirmed from now on May 13, 2021. 5.4735-0.2565 (-4.48%) Upgrade to Real-Time Regular Market . There is no upcoming split for Adaptimmune Therapeutics. 2.00. This is 0.36% less than the trading day before Thursday, 28th Jan 2021. Today, Raymond James set its price target on Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to $16.00 per share. On November 05, 2020 "SVB Leerink" gave "Market Perform" rating for ADAP. Based on analysts offering 12 month price targets for ADAP in the last 3 months. Adaptimmune Therapeutics has a 52 week low of $2.00 and a 52 week high of $13.40. The current projected Adaptimmune Ther target price consensus is 9.25 with 4 analyst opinions. Ergobaby 360 All Carry Positions Ergonomic Cool Air Mesh Baby Carrier. Adaptimmune Therapeutics PLC's upside potential (average analyst target price relative to current price) is higher than 87.96% of all US stocks. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptimmune Therapeutics. TipRanks lets you see the track record and measured performance of any analyst or blogger you come across, so you know who to trust! Ergobaby Aura Baby Wrap Twinkle. AHCO Price Target Upside: 35.08% upside: 28.21% upside: 24.93% upside: 31.72% upside: AdaptHealth (NASDAQ:AHCO) Consensus Price Target History. Based on analysts offering 12 month price targets for ADAP in the last 3 months. The latest price target for Adaptimmune Therapeutics (NASDAQ: ADAP) was reported by SVB Leerink on 2020-11-05. The price target was set to $10.00 → $6.00. Ergobaby. Today ||| 52-Week Range. Trading levels for ADAP . Use the tables below to see what analysts covering Adaptimmune Therapeutics PLC think about its future price and what recommendations they have for investors and traders. 07:24 AM ET. Ergobaby. The average analyst price target of ADAP is higher than 24.05% of all US stocks. On top of this, the average price target is $13.33, suggesting robust growth of ~236% from the current price of $3.97. $139.99 - $140.00. Exxon Mobil Corp. XOM, +3.87% on Wednesday outlined its plans to adapt to a lower carbon future with details of capital spending and earnings expectations for the next four years. ADAP -- USA Stock : USD 6.29 0.31 5.18% : ... Target Price: High: 5.00: 9.25: 17.00: Details. Ratings...FREE! Further, Adaptimmune Therapeutics plc (ADAP) has a beta value of 2.21, and an average true range (ATR) of 0.45. Headlines for Adaptimmune Therapeutics PLC ADR (NAS:ADAP) News for Adaptimmune Therapeutics PLC ADR. for only. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. Based on our forecasts, a long-term increase is expected, the "ADAP" stock price prognosis for 2026-02-27 is 7.687 USD. Other companies in Adaptimmune Therapeutics’s space includes: KalVista Pharmaceuticals (NASDAQ:KALV), Avidity Biosciences (NASDAQ:RNA) and Curis (NASDAQ:CRIS). Did Adaptimmune Therapeutics' (NASDAQ:ADAP) Share Price Deserve to Gain 52%? These price ends are -11.11% and +151.85% off the current price level respectively, although investors could be excited at the prospect of a +77.78% if the ADAP share price touches on the median price of $12. Adapt is a unified sales acceleration platform with the industry-leading products Lead Builder, Prospector and Engage. Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price reduced by Raymond James from $16.00 to $6.00 in a report published on Tuesday, May 7th, The Fly reports. The average price target represents a 150.00% increase from the last price of $3.20. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Big Cap Pro. Adaptimmune Therapeutics price target cut to $9 from $12 at SunTrust Robinson Humphrey Ergobaby Aura Wrap - Pure Black. Close price at the end of the last trading day (Friday, 29th Jan 2021) of the ADAP stock was $5.46. appreciate its future potential. The most common way Adaptimmune Ther Ads analysts use to provide recommendation to the public is financial statements analysis. Choose options. The new note on the price target was released on August 02, 2019, representing the official price target for Adaptimmune Therapeutics plc stock. In depth view into ADAP (Adaptimmune Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. 81. The dark blue line represents the company's actual price. 4.6 out of 5 stars with 744 reviews. The new note on the price target was released on August 02, 2019, representing the official price target for Adaptimmune Therapeutics plc stock. Monthly Subscription. About ADAP. 1,457,161 shares of the company’s stock were exchanged, compared to its average volume of 1,256,764. Choose from contactless Same Day Delivery, Drive Up and more. Adaptimmune Therapeutics PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. Morgan Stanley has the highest price target set, predicting ADAP will reach $42.00 in the next twelve months. The average analyst price target currently stands at $10 (13% downside potential). ADI price target in 14 days: 515.147 ZAR* upside and 472.019 ZAR* downside. The chart below shows how a company's share price and consensus price target have changed over time. 02:05 PM ET. View Adaptimmune Therapeutics PLC ADAP investment & stock information. ADAP declines -5.7% a week on average for past two weeks. Sign Up to See 87 institutions hold shares in Adaptimmune Therapeutics plc (ADAP), with 338.2k shares held by insiders accounting for 0.22% while institutional investors hold 84.23% of the company’s shares. The average price target is $8.00 with a high forecast of $8.00 and a low forecast of $8.00. 4.7 out of 5 stars with 410 reviews. Login Adaptimmune Therapeutics reported earnings per share … 17 Stocks Moving In Tuesday's After-Hours Session, 12 Health Care Stocks Moving In Tuesday's After-Market Session. Did Adaptimmune Therapeutics' (NASDAQ:ADAP) Share Price Deserve to Gain 52%? See In depth view into Adaptimmune Therapeutics Price Target Upside (Daily) including historical data from 2015, charts, stats and industry comps. A high-level overview of Adaptimmune Therapeutics plc (ADAP) stock. There are no upcoming dividends for Adaptimmune Therapeutics. A number of other analysts also recently issued reports on the stock. 4.7 out of 5 stars with 3 reviews. For a wide assortment of Ergobaby visit Target.com today. Rotation from value to growth for small cap. Analysts Set Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) Price Target at $8.00 Citizens Community Bancorp Inc. (NASDAQ:CZWI) Expected to … Adaptimmune Therapeutics PLC's NA is higher than practically none of all US stocks. The lighter blue line represents the … With a 5-year investment, the revenue is expected to be around +53.43%. Ergobaby. Adaptimmune stock price target raised to $9 from $3 at Mizuho Jun. You can unlock it all now. Best deals to access real time data! It focused on providing novel cell therapies to patients, particularly in solid tumors. Insider Monkey +6.88%. Free trial. Adaptimmune Therapeutics PLC's number of analysts covering the stock is higher than 77.91% of stocks in the small market cap category.
Juul Compatible Pods Near Me, Land For Sale Dorset Auction, Juul Pod Flavors 2020, Juul Price In 7 Eleven, Homework Pass Clipart, Where Can You Use Metal Detectors, Nas Jrb New Orleans Housing, Juul Compatible Pods Near Me, List Of Independent Pharmacies In Usa,